Delivery of opioids through an inhalation route
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/12
A61K-009/14
A61M-015/00
출원번호
US-0621397
(2007-01-09)
등록번호
US-7468179
(2008-12-23)
발명자
/ 주소
Rabinowitz,Joshua D.
Zaffaroni,Alejandro C.
출원인 / 주소
Alexza Pharmaceuticals, Inc.
대리인 / 주소
Swanson & Bratschun, L.L.C.
인용정보
피인용 횟수 :
39인용 특허 :
150
초록▼
The present invention relates to the delivery of opioids through an inhalation route. Specifically, it relates to aerosols containing opioids that are used in inhalation therapy. In a method aspect of the present invention, an opioid is delivered to a patient through an inhalation route. The method
The present invention relates to the delivery of opioids through an inhalation route. Specifically, it relates to aerosols containing opioids that are used in inhalation therapy. In a method aspect of the present invention, an opioid is delivered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an opioid, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% opioid degradation products. In a kit aspect of the present invention, a kit for delivering an opioid through an inhalation route is provided which comprises: a) a thin layer of an opioid and b) a device for dispensing said thin layer as a condensation aerosol.
대표청구항▼
The invention claimed is: 1. A condensation aerosol for delivery of naltrexone formed by heating a composition containing naltrexone coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 per
The invention claimed is: 1. A condensation aerosol for delivery of naltrexone formed by heating a composition containing naltrexone coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of naltrexone and less than 5 percent by weight of naltrexone degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 2. The condensation aerosol according to claim 1, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 3. The condensation aerosol according to claim 2, wherein the condensing comprises allowing the vapor to cool. 4. A condensation aerosol for delivery of buprenorphine formed by heating a composition containing buprenorphine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of buprenorphine and less than 5 percent by weight of buprenorphine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 5. The condensation aerosol according to claim 4, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 6. The condensation aerosol according to claim 5, wherein the condensing comprises allowing the vapor to cool. 7. A condensation aerosol for delivery of naloxone formed by heating a composition containing naloxone coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of naloxone and less than 5 percent by weight of naloxone degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 8. The condensation aerosol according to claim 7, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 9. The condensation aerosol according to claim 8, wherein the condensing comprises allowing the vapor to cool. 10. A condensation aerosol for delivery of butorphanol formed by heating a composition containing butorphanol coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of butorphanol and less than 5 percent by weight of butorphanol degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 11. The condensation aerosol according to claim 10, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 12. The condensation aerosol according to claim 11, wherein the condensing comprises allowing the vapor to cool. 13. A condensation aerosol for delivery of hydromorphone formed by heating a composition containing hydromorphone coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of hydromorphone and less than 5 percent by weight of hydromorphone degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 14. The condensation aerosol according to claim 13, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 15. The condensation aerosol according to claim 14, wherein the condensing comprises allowing the vapor to cool. 16. A condensation aerosol for delivery of oxycodone formed by heating a composition containing oxycodone coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of oxycodone and less than 5 percent by weight of oxycodone degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 17. The condensation aerosol according to claim 16, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 18. The condensation aerosol according to claim 17, wherein the condensing comprises allowing the vapor to cool. 19. A condensation aerosol for delivery of methadone formed by heating a composition containing methadone coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of methadone and less than 5 percent by weight of methadone degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 20. The condensation aerosol according to claim 19, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 21. The condensation aerosol according to claim 20, wherein the condensing comprises allowing the vapor to cool. 22. A condensation aerosol for delivery of remifentanil formed by heating a composition containing remifentanil coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of remifentanil and less than 5 percent by weight of remifentanil degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 23. The condensation aerosol according to claim 22, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 24. The condensation aerosol according to claim 23, wherein the condensing comprises allowing the vapor to cool. 25. A condensation aerosol for delivery of sufentanil formed by heating a composition containing sufentanil coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of sufentanil and less than 5 percent by weight of sufentanil degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 26. The condensation aerosol according to claim 25, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 27. The condensation aerosol according to claim 26, wherein the condensing comprises allowing the vapor to cool. 28. A condensation aerosol for delivery of nalbuphine formed by heating a composition containing nalbuphine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of nalbuphine and less than 5 percent by weight of nalbuphine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 29. The condensation aerosol according to claim 28, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 30. The condensation aerosol according to claim 29, wherein the condensing comprises allowing the vapor to cool. 31. A condensation aerosol for delivery of fentanyl formed by heating a composition containing fentanyl coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of fentanyl and less than 5 percent by weight of fentanyl degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 32. The condensation aerosol according to claim 31, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 33. The condensation aerosol according to claim 32, wherein the condensing comprises allowing the vapor to cool. 34. A method of forming a naltrex one containing aerosol comprising: (a) heating a composition containing naltrexone coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of naltrexone degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 35. The method according to claim 34, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 36. The method according to claim 35, wherein the coated composition comprises at least 10 percent by weight of naltrexone. 37. A method of forming a buprenorphine containing aerosol comprising: (a) heating a composition containing buprenorphine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of buprenorphine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 38. The method according to claim 37, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 39. The method according to claim 38, wherein the coated composition comprises at least 10 percent by weight of buprenorphine. 40. A method of forming a naloxone containing aerosol comprising: (a) heating a composition containing naloxone coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of naloxone degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 41. The method according to claim 40, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 42. The method according to claim 41, wherein the coated composition comprises at least 10 percent by weight of naloxone. 43. A method of forming a butorphanol containing aerosol comprising: (a) heating a composition containing butorphanol coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of butorphanol degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 44. The method according to claim 43, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 45. The method according to claim 44, wherein the coated composition comprises at least 10 percent by weight of butorphanol. 46. A method of forming a hydromorphone containing aerosol comprising: (a) heating a composition containing hydromorphone coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of hydromorphone degradation product% and the condensation aerosol has an MMAD of less than 5 microns. 47. The method according to claim 46, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 48. The method according to claim 47, wherein the coated composition comprises at least 10 percent by weight of hydromorphone. 49. A method of forming an oxycodone containing aerosol comprising: (a) heating a composition containing oxycodone coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of oxycodone degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 50. The method according to claim 49, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 51. The method according to claim 50, wherein the coated composition comprises at least 10 percent by weight of oxycodone. 52. A method of forming a methadone containing aerosol comprising: (a) heating a composition containing methadone coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of methadone degradation product% and the condensation aerosol has an MMAD of less than 5 microns. 53. The method according to claim 52, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 54. The method according to claim 53, wherein the coated composition comprises at least 10 percent by weight of methadone. 55. A method of forming a remifentanil containing aerosol comprising: (a) heating a composition containing remifentanil coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of remifentanil degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 56. The method according to claim 55, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 57. The method according to claim 56, wherein the coated composition comprises at least 10 percent by weight of remifentanil. 58. A method of forming a sufentanil containing aerosol comprising: (a) heating a composition containing sufentanil coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of sufentanil degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 59. The method according to claim 58, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 60. The method according to claim 59, wherein the coated composition comprises at least 10 percent by weight of sufentanil. 61. A method of forming a fentanyl containing aerosol comprising: (a) heating a composition containing fentanyl coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of fentanyl degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 62. The method according to claim 61, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 63. The method according to claim 62, wherein the coated composition comprises at least 10 percent by weight of fentanyl. 64. A method of forming a nalbuphine containing aerosol comprising: (a) heating a composition containing nalbuphine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of nalbuphine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 65. The method according to claim 64, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 66. The method according to claim 65, wherein the coated composition comprises at least 10 percent by weight of nalbuphine. 67. The method according to claim 35, wherein the condensing comprises allowing the vapor to cool. 68. The method according to claim 38, wherein the condensing comprises allowing the vapor to cool. 69. The method according to claim 41, wherein the condensing comprises allowing the vapor to cool. 70. The method according to claim 44, wherein the condensing comprises allowing the vapor to cool. 71. The method according to claim 47, wherein the condensing comprises allowing the vapor to cool. 72. The method according to claim 50, wherein the condensing comprises allowing the vapor to cool. 73. The method according to claim 53, wherein the condensing comprises allowing the vapor to cool. 74. The method according to claim 56, wherein the condensing comprises allowing the vapor to cool. 75. The method according to claim 59, wherein the condensing comprises allowing the vapor to cool. 76. The method according to claim 62, wherein the condensing comprises allowing the vapor to cool. 77. The method according to claim 65, wherein the condensing comprises allowing the vapor to cool. 78. A method of forming a drug containing aerosol comprising: (a) heating a composition containing the drug and a pharmaceutically acceptable excipient coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of naltrexone, buprenorphine, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, methadone, remifentanil, sufentanil, and fentanyl, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 79. The method according to claim 78, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 80. The method according to claim 79, wherein the coated composition comprises at least 10 percent by weight of the drug. 81. The method according to claim 79, wherein the condensing comprises allowing the vapor to cool. 82. A method of forming a drug containing aerosol comprising: (a) heating a composition containing a salt form of the drug coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of naltrexone, buprenorphine, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, methadone, remifentanil, sufentanil, and fentanyl, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 83. The method according to claim 82, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 84. The method according to claim 83, wherein the coated composition comprises at least 10 percent by weight of the salt form of the drug. 85. The method according to claim 83, wherein the condensing comprises allowing the vapor to cool. 86. A method of forming a drug containing aerosol comprising: (a) heating a composition containing the drug coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of naltrexone, buprenorphine, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, methadone, remifentanil, sufentanil, and fentanyl, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 87. The method according to claim 86, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 88. The method according to claim 87, wherein the condensation aerosol is formed at a rate greater than 0.75 mg/second. 89. The method according to claim 88, wherein the condensation aerosol is formed at a rate greater than 1 mg/second. 90. The method according to claim 89, wherein the condensation aerosol is formed at a rate greater than 2 mg/second. 91. The method according to claim 86, wherein the condensing comprises allowing the vapor to cool.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (150)
Sands George H., 5HT 1 receptor agonists and metoclopramide for the treatment of migraine.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Clearman Jack F. (Blakely GA) Chiou Joseph J. (Clemmons NC) Williams Darrell D. (Winston-Salem NC) Casey William J. (Clemmons NC) Gentry Thomas L. (Winston-Salem NC) Squires William C. (Winston-Salem, Aerosol delivery article.
Roberts Donald L. (Winston-Salem NC) Morrison Carl C. (Winston-Salem NC) Brooks Johnny L. (Winston-Salem NC) Crooks Evon L. (Winston-Salem NC) Ingebrethsen Bradley J. (Winston-Salem NC), Aerosol delivery article.
Horvath, Raymond F.; Tran, Jennifer; De Lombaert, Stephane; Hodgetts, Kevin J.; Carpino, Philip A.; Griffith, David A., Certain alkylene diamine-substituted heterocycles.
Hodges, Craig C.; Lloyd, Peter M.; Mufson, Daniel; Rogers, Daniel D.; Wensley, Martin J., Delivery of aerosols containing small particles through an inhalation route.
Hale, Ron L.; Rabinowitz, Joshua D.; Solas, Dennis W.; Zaffaroni, Alejandro C., Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route.
Hale,Ron L.; Rabinowitz,Joshua D.; Solas,Dennis W.; Zaffaroni,Alejandro C., Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route.
Hale,Ron L.; Rabinowitz,Joshua D.; Solas,Dennis W.; Zaffaroni,Alejandro C., Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route.
Potter Dennis L. (Kernersville NC) Raker Mark L. (Clemmons NC) Ridings Henry T. (Lewisville NC) Sensabaugh ; Jr. Andrew J. (Winston-Salem NC) Westmoreland Amos E. (Winston-Salem NC) Woods Donna K. (W, Drug delivery article.
Hodson Peter David (Trowell Park GB3) Smith David Keith (Loughborough GB3) Wass Anthony Charles Lammond (Duddington GB3), Dry powder inhalation device having deagglomeration/aerosolization structure responsive to patient inhalation.
Sprinkel F. Murphy (Glen Allen VA) Das Amitabh (Midlothian VA) Fleischhauer Grier S. (Midlothian VA) Grollimund Everett C. (Midlothian VA) Houck ; Jr. Willie G. (Richmond VA) Lipowicz Peter J. (Midlo, Electrical lighter with a rotatable tobacco supply.
Higgins Charles T. (Richmond VA) Raymond Wynn R. (Chesterfield VA) Sprinkel Francis M. (Glen Allen VA), Electrical smoking article using liquid tobacco flavor medium delivery system.
Counts Mary E. (Richmond VA) LaRoy Bernard C. (Richmond VA) Losee ; Jr. D. Bruce (Richmond VA) Morgan Constance H. (Midlothian VA) Smith Ulysses (Midlothian VA) Sprinkel ; Jr. F. Murphy (Glen Allen V, Flavor generating article.
Counts Mary E. (Richmond VA) Hajaligol Mohammad R. (Richmond VA) Morgan Constance H. (Midlothian VA) Smith Ulysses (Midlothian VA) Sprinkel Francis M. (Glen Allen VA) Utsch Francis V. (Midlothian VA), Flavor-delivery article.
Weers Jeffry G. ; Dellamary Luis A. ; Tarara Thomas E. ; Trevino Leo A. ; Ranney Helen M., Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents.
Rubsamen Reid M. (Berkeley CA) Lloyd Lester J. (Orinda CA) Johansson Eric T. (Dublin CA), Lockout device for controlled release of drug from patient-activated dispenser.
Radhakrishnan Ramachandran (Fremont CA) Mihalko Paul J. (Fremont CA) Abra Robert M. (San Francisco CA), Method and apparatus for administering dehydrated liposomes by inhalation.
Banerjee Chandra K. (Pfafftown NC) Farrier Ernest G. (Winston-Salem NC) Ridings Henry T. (Lewisville NC) Sensabaugh ; Jr. Andrew J. (Winston-Salem NC) Shannon Michael D. (Lewisville NC) Shelar Gary R, Method for making aerosol generating cartridge.
Olsson Sven-Gunnar,SEX ; Rydgren Goran,SEX ; Larsson Anders,SEX ; Niininen Tarmo,SEX, Method for vaporizing an anesthetic liquid and vaporizer operating according to the method.
Serrano Mark A. (Greenwich CT) Houghton Kenneth S. (Midlothian VA) Lanzillotti Harry V. (Midlothian VA) Sanders Edward B. (Richmond VA) Lilly ; Jr. A. Clifton (Chesterfield VA) Hayward Charles R. (Mi, Smoking article.
Sutton Andrew D.,GBX ; Johnson Richard A.,GBX ; Senior Peter J.,GBX ; Heath David,GBX, Spray-dried microparticles and their use as therapeutic vehicles.
Lloyd Lester J. (Orinda CA) Lloyd Peter M. (Oakland CA) Rubsamen Reid M. (Berkeley CA) Schuster Jeffrey A. (Berkeley CA), Systems for the intrapulmonary delivery of aerosolized aqueous formulations.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Lu, Amy T.; Myers, Daniel J.; Rabinowitz, Joshua D.; Wensley, Martin J.; McKinney, Jeffrey A.; Zaffaroni, Alejandro C., Drug condensation aerosols and kits.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Lu, Amy T.; Myers, Daniel J.; Rabinowitz, Joshua D.; Wensley, Martin J.; McKinney, Jeffrey A.; Zaffaroni, Alejandro C., Drug condensation aerosols and kits.
Poutiatine, Andrew I.; Rampersaud, Charles; Schreck, Thomas; Kolosi, William; Retailleau, Sascha, Drug storage and dispensing devices and systems comprising the same.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Mufson, Daniel; Rogers, Daniel D.; Song, Soonho; Wensley, Martin J.; Myers, Daniel J.; McKinney, Jeffrey A.; Quintana, Reynaldo J.; Rabinowitz, Joshua D., Method of forming an aerosol for inhalation delivery.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Mufson, Daniel; Rogers, Daniel D.; Song, Soonho; Wensley, Martin J.; Myers, Daniel J.; McKinney, Jeffrey A.; Quintana, Reynaldo J.; Rabinowitz, Joshua D., Method of forming an aerosol for inhalation delivery.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Mufson, Daniel; Rogers, Daniel D.; Song, Soonho; Wensley, Martin J.; Myers, Daniel J.; McKinney, Jeffrey A.; Quintana, Reynaldo J.; Rabinowitz, Joshua D., Method of forming an aerosol for inhalation delivery.
Palmer, Pamela; Poutiatine, Andrew I.; Rampersaud, Charles; Edwards, Bruce; Chiu, Edmond; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry, Method of moving a delivery member of a dispensing device for administration of oral transmucosal dosage forms.
Palmer, Pamela; Poutiatine, Andrew I; Rampersaud, Charles; Edwards, Bruce; Chiu, Edmond; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry, Methods for administering small volume oral transmucosal dosage forms using a dispensing device.
Cross, Stephen D.; Herbette, Mathieu; Kelly, Andrew J. G.; Myers, Daniel J.; Shen, William W.; Timmons, Ryan D.; Tom, Curtis; Virgili, Justin M.; Wensley, Martin J., Multiple dose condensation aerosol devices and methods of forming condensation aerosols.
Hale, Ron L.; Lloyd, Peter M.; Lu, Amy; Myers, Daniel J.; Quintana, Reynaldo J.; Rabinowitz, Joshua D.; Solas, Dennis W.; Song, Soonho; Tom, Curtis; Wensley, Martin J., Rapid-heating drug delivery article and method of use.
Hale, Ron L.; Lloyd, Peter M.; Lu, Amy T.; Rabinowitz, Joshua D.; Wensley, Martin J., Respiratory drug condensation aerosols and methods of making and using them.
Damani, Ramesh; Hale, Ron L.; Myers, Daniel J.; Quintana, Reynaldo J.; Solas, Dennis W.; Song, Soonho; Soni, Pravin; Tom, Curtis; Sharma, Kirshnamohan, Self-contained heating unit and drug-supply unit employing same.
Damani, Ramesh; Hale, Ron L.; Myers, Daniel J.; Quintana, Reynaldo J.; Solas, Dennis W.; Song, Soonho; Soni, Pravin; Tom, Curtis; Sharma, Krishnamohan, Self-contained heating unit and drug-supply unit employing same.
Damani, Ramesh; Hale, Ron L.; Myers, Daniel J.; Quintana, Reynaldo J.; Solas, Dennis W.; Song, Soonho; Soni, Pravin; Tom, Curtis; Sharma, Krishnamohan, Self-contained heating unit and drug-supply unit employing same.
Palmer, Pamela; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry; Poutiatine, Andrew I., Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain.
Palmer, Pamela; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry; Poutiatine, Andrew I., Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain.
Palmer, Pamela; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry; Poutiatine, Andrew I., Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain.
Poutiatine, Andrew; Edwards, Bruce; Rampersaud, Charles; Palmer, Pamela; Blackwood, Bradley; Yaffe, Benjamin K., Storage and dispensing devices for administration of oral transmucosal dosage forms.
Poutiatine, Andrew; Edwards, Bruce; Rampersaud, Charles; Palmer, Pamela; Blackwood, Bradley; Yaffe, Benjamin K., Storage and dispensing devices for administration of oral transmucosal dosage forms.
Pushpala, Shamim; Hamel, Larry; Tzannis, Stelios; Cruz, Evangeline, Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.